Brainstorm Cell (BCLI)

May 7, 2025, 6:30 AM EDT - 7 days ago

BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025

May 6, 2025, 7:00 AM EDT - 8 days ago

BrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit

Apr 29, 2025, 6:30 AM EDT - 15 days ago

BrainStorm's NurOwn® Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting

Apr 10, 2025, 7:30 AM EDT - 4 weeks ago

BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS

Mar 31, 2025, 10:48 AM EDT - 6 weeks ago

Brainstorm Cell Therapeutics Inc. (BCLI) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 7:00 AM EDT - 6 weeks ago

BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

Mar 26, 2025, 8:15 AM EDT - 7 weeks ago

BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq

Mar 24, 2025, 7:00 AM EDT - 7 weeks ago

BrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update

Dec 30, 2024, 8:00 AM EST - 4 months ago

BrainStorm Issues 2024 Letter to Shareholders

Dec 9, 2024, 7:00 AM EST - 5 months ago

BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update

Dec 3, 2024, 7:00 AM EST - 5 months ago

BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology

Dec 2, 2024, 7:00 AM EST - 5 months ago

BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024

Nov 14, 2024, 4:30 PM EST - 6 months ago

BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 11, 2024, 6:00 AM EST - 6 months ago

BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

PLUR

Oct 30, 2024, 6:00 AM EDT - 7 months ago

BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Oct 28, 2024, 6:00 AM EDT - 7 months ago

BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting

Oct 7, 2024, 7:00 AM EDT - 7 months ago

BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit

Sep 24, 2024, 6:00 AM EDT - 8 months ago

BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting

Aug 14, 2024, 12:08 PM EDT - 9 months ago

Brainstorm Cell Therapeutics Inc. (BCLI) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 7:05 AM EDT - 9 months ago

BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 7, 2024, 6:00 AM EDT - 10 months ago

BrainStorm Cell Therapeutics to Announce Second Quarter Results and Provide a Corporate Update

Jul 24, 2024, 8:30 AM EDT - 10 months ago

BCLI Update - Progress Supports Our 10x Plus Value Range Potential

Jul 8, 2024, 10:12 AM EDT - 11 months ago

Brainstorm Cell Therapeutics Inc. (BCLI) Corporate Mid-Year Update on NurOwn Program (Transcript)

Jul 1, 2024, 6:00 AM EDT - 11 months ago

BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program

Jun 27, 2024, 9:15 AM EDT - 11 months ago

BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering

Jun 26, 2024, 8:00 AM EDT - 11 months ago

BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial

Jun 20, 2024, 6:00 AM EDT - 11 months ago

BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer

Jun 14, 2024, 12:01 PM EDT - 11 months ago

BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation

May 20, 2024, 6:00 AM EDT - 1 year ago

BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn

May 14, 2024, 4:30 PM EDT - 1 year ago

BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Apr 16, 2024, 6:30 PM EDT - 1 year ago

BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn

Apr 11, 2024, 6:00 AM EDT - 1 year ago

BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule

Apr 10, 2024, 6:00 AM EDT - 1 year ago

BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS

Apr 9, 2024, 6:00 AM EDT - 1 year ago

BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS

Apr 8, 2024, 6:00 AM EDT - 1 year ago

BrainStorm Cell Therapeutics to Provide Update on NurOwn Program

Apr 1, 2024, 8:05 AM EDT - 1 year ago

BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update

Feb 27, 2024, 6:30 AM EST - 1 year ago

BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference

Feb 23, 2024, 6:00 AM EST - 1 year ago

BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS

Feb 13, 2024, 6:30 AM EST - 1 year ago

BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum

Dec 28, 2023, 9:00 AM EST - 1 year ago

BRAINSTORM INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Discuss Their Options

Dec 26, 2023, 7:30 AM EST - 1 year ago

BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments

Dec 20, 2023, 9:00 AM EST - 1 year ago

BrainStorm Issues 2023 Letter to Shareholders

Dec 7, 2023, 8:40 AM EST - 1 year ago

BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS

Dec 4, 2023, 7:00 AM EST - 1 year ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Reminds Investors in Brainstorm Cell Therapeutics Inc. with Losses In Excess of $500,000 to Contact the Firm

Nov 30, 2023, 8:30 AM EST - 1 year ago

BRAINSTORM INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their Options